Latest Breaking News On - Development for the treatment of autoimmune diseases - Page 1 : comparemela.com

Third-Quarter 2022 Results: Net Sales of $925.4 Million GAAP Net Income of $135.8 Million; Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones

United statesGeoff curtisTim walbertTina venturaRay gordonErin linnihanCompanies that careShare repurchase programSubcutaneous sc administration trialAmerican college of rheumatologyKey clinical development programsDevelopment for the treatment of autoimmune diseasesResearch in multiple sclerosisClinical programApotex incDivision of corporation